The UAE’s Ministry of Health and Prevention (MOHAP) has announced the official registration of the Beijing Institute of Biological Product’s inactivated COVID-19 vaccine in a major step towards combating the global pandemic.
The decision was taken in response to the application from Sinopharm CNBG.
This decision is a vote of confidence in the safety and efficiency in the vaccination by the UAE's Health Authorities.
MOHAP has collaborated with the Department of Health Abu Dhabi to review Sinopharm CNBG’s interim analysis of the phase III trials.
The result shows that the Beijing Institute of Biological Product’s inactivated vaccine to have 86 per cent efficacy against COVID-19 infection.
The analysis also shows the vaccine to have 99 per cent seroconversion rate of neutralising antibody and 100 per cent effectiveness in preventing moderate and severe cases of the disease. The analysis has also shown no serious safety concerns.
This vaccine was granted Emergency Use Authorisation (EUA), since September by MOHAP to protect frontline workers most at risk of COVID-19.
The UAE is also conducting Post Authorisation Safety Study (PASS), and Post Authorisation Efficacy Study (PAES), of its EUA programme. These ongoing studies show similar safety and efficacy profiles as the interim analysis.
The #4Humanity phase III trials have included 31,000 volunteers across 125 nationalities in the UAE alone.
The EUA vaccination programme has effectively safeguarded the UAE frontline workers.